drugset / Trial / NCT02253953

Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers

NCT02253953

Phase 1 Completed 62 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Assessment of the effect of two times oral 100 mg ritonavir capsules on pharmacokinetics of a single dose of BILR 355 BS dissolved in PEG 400

Timeline

Start
2002-11
Primary completion
2003-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BILR 355 BS Unknown 5 mg Oral
Subject BILR 355 BS Unknown 12.5 mg Oral
Subject BILR 355 BS Unknown 25 mg Oral
Subject BILR 355 BS Unknown 100 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral

Indications

No indication recorded.